Business Wire

FUCHS-PETROLUB-SE

15.11.2021 10:02:05 CET | Business Wire | Press release

Share
FUCHS Group announces new design for automotive lubricants: better orientation, better handling, gentler use of resources

The FUCHS Group, which operates globally in the lubricants industry, brings new small packs for the automotive sector onto the market, maximizing customer benefits: new labels for better orientation, ergonomic design for better handling, and gentle on resources thanks to the use of recycled material. The new small packs will be implemented gradually in the FUCHS companies from November 15, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005059/en/

The range of lubricant products in the automotive sector is enormous – and for customers it's getting harder and harder to find what they need. The new small packs for all automotive FUCHS product brands – TITAN, AGRIFARM, MAINTAIN, PLANTO, and SILKOLENE – rise to this challenge: The Group has optimized its small packs globally for the quantities 1, 4, and 5 liters, not just visually but also in terms of handling and environmental friendliness. "The unique new design makes it easier for our customers to choose the right product, improves user-friendliness, and saves on resources," sums up Krisztián Rada, Head of Automotive Aftermarket Division.

Easy to choose

The new clearly structured design of the labels enables customers to identify all the relevant information at a glance. Colors, images, and pictograms help with orientation. For instance, the quality levels of the products are clearly indicated by the color codes gold, silver, and bronze. The most important information the customer needs to know about the lubricant is given in concise and comprehensible way, such as the viscosity of the product and area of application – for cars, trucks, or tractors.

Easy to use

The new ergonomically shaped bottles are easy to open without tools, fit better in the hand, and are easier for the user to handle. For example, the enlarged opening of the bottle and an optimized neck design allow accurate filling with no drops. Two handles make the 4 and 5-liter bottles more comfortable to carry and facilitate filling. What's more, the new tamper-resistant cap ensures that the bottle has not been opened before and that if FUCHS is written on it, there is FUCHS inside it.

Easy on the environment :

FUCHS has been pursuing its sustainability strategy for almost ten years now, with the objective of carbon neutrality according to the "avoid – reduce – compensate" principle. As such, all FUCHS lubricants in the Group's plants are produced carbon-neutrally. The bottle material of the new small packs consists of up to 30 percent recycled material (PCR) and is 100-percent recyclable. The improved bottle shape of the bottle also makes it possible to pour out even the smallest remaining volume of fluid, allowing complete emptying of the bottles. "Our new small packs are not just intended to be more user-friendly but also contribute to avoiding waste, enable materials to be recycled, and help to reduce carbon footprints. FUCHS will continue to work toward making our packaging continuously more sustainable in the future, too," says Markus Garb, Vice President Sustainability, stating a further objective of the innovation.

The following information material is available online:

https://www.fuchs.com/group/products-industries/product-program/automotive-lubricants/new-automotive-small-packs/

About FUCHS

FUCHS develops, produces and markets high-grade lubricants and related specialties for virtually all industries and areas of application. The company, which was founded in Mannheim in 1931, employs around 6,000 people worldwide at 58 operating companies. FUCHS is the world's largest independent lubricant manufacturer. The most important markets in terms of sales revenue are Western Europe, Asia and North America.

Link:

ClickThru

Social Media:

https://www.facebook.com/FUCHSDeutschland/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye